GOSS: Gossamer Bio Inc Price to Sales
The price-to-sales multiple for Gossamer Bio, Inc. (GOSS) reflects the impact of stringent FDA oversight and high development costs on the share price, with the value holding at 0.90. The asset's price action is independent of broader economic trends, relying instead on the success of clinical trials. Business stability is based on the patent protection of a single drug, creating a high probability of a binary outcome for the investor.
Metric breakdowns and analytics for Gossamer Corp (GOSS)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Gossamer Bio, Inc.|GOSS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Gossamer Bio Corp.|GOSS - Company Aggregate Debts|Debts to Book Capitalization Gossamer Corp|GOSS - Company Long-Term Debt|Company Current Liabilities Gossamer Bio|Immediate Liquidity gossamerbio.com
- earnings and market multiples details:
GOSS - Company Net Income|Expected Net Income Gossamer Bio, Inc.|GOSS - Price to Earnings Ratio|Future Price to Earnings Multiple Gossamer Bio Inc|GOSS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gossamer Corp|GOSS - Operating profit EBITDA|Net earnings per share for the last four quarters Gossamer Bio|GOSS - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months gossamerbio.com|GOSS - Net earnings per share growth this year|Expected earnings per share trend next year Gossamer Bio, Inc.
- total revenue and sales volume data:
General company analysis:GOSS gossamerbio.com
When constructing a long-term portfolio, fundamental screening requires a strict correlation between an asset's market value and its actual trading turnover. This ratio measures capitalization per unit of revenue, allowing for an assessment of whether an asset is overbought, which is critical for Gossamer Bio, Inc. (GOSS), as it develops a unique therapy system for pulmonary hypertension, and is clearly reflected in the dynamics of the market cap-to-revenue ratio.
Competitors of Gossamer Bio, Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Multiple Protagonist Corp (PTGX)|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Adaptive Biotech (ADPT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Celldex (CLDX)|Price-to-Revenue Coefficient Aurinia Corp|P/S Multiple BCRX (BioCryst)|P/S Multiple veratx.com VERA|DNTH - Price-to-Revenue Ratio|Pharvaris NV (PHVS) - Market Cap to Revenue|ABCL: P/S Multiple|Price to Sales Tourmaline (TRML)|Price-to-Revenue Ratio Precigen, Inc.|PHAR: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio - Price-to-Revenue Ratio|KalVista Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient septerna.com SEPN|Pieris Pharmaceuticals, Inc. (PVLA) - Price-to-Revenue Ratio|Price to Sales Savara Inc (SVRA)|Market Cap to Revenue RIGL|ANAB: Market Capitalization-to-Revenue Ratio|P/S Multiple ATXS|Price-to-Revenue Coefficient engene.com|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO: Market Cap to Revenue Ratio|Aclaris - P/S Multiple|Kyverna Therapeutics, Inc (KYTX) - Market Cap to Revenue|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|CABA - Price-to-Revenue Coefficient|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|THTX - Price-to-Revenue Multiple|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN - Price to Sales|Price-to-Revenue Ratio Agenus AGEN|Price-to-Revenue Coefficient climbbio.com (CLYM)|ZURA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient aTyr Pharma Inc ATYR|adagene.com (ADAG) - Price-to-Revenue Ratio|Price-to-Sales Ratio IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - P/S Multiple|EQ: Market Capitalization-to-Revenue Ratio|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|Price-to-Revenue Ratio Atara Bio ATRA|Market Capitalization-to-Revenue Ratio IFRX|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU: P/S Multiple|INmune Bio Inc (INMB) - P/S Multiple|Market Cap to Revenue BRNS|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|Price-to-Revenue Coefficient akaritx.com|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Ratio BOLT (Bolt Bio)|P/S Multiple HCWB|APVO - Price to Sales|P/S Multiple AIM (AIM ImmunoTech Inc.)|Price-to-Revenue Multiple Aditxt Inc.|GRI - Price-to-Revenue Ratio|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|REVB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com (SCNI) - Price-to-Revenue Coefficient|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|HOOK - Market Cap to Revenue|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue THRD
